Startup aims to disrupt asthma, COPD space with digital inhaler
Formed just two years ago, pharma startup Pneuma Respiratory is developing a digital inhaler that it touts as the first of its kind. The company is looking to bring its technology to the more than 40 million people who suffer from asthma or chronic obstructive pulmonary disease in the U.S. They’re stepping into a highly competitive market, largely dominated by companies like GlaxoSmithKline (NYSE:GSK) and Merck (NYSE:MRK). Get the full story at our sister site, Drug Delivery Business News. The post Startup aims to disrupt asthma, COPD space with digital inhaler appeared first on MassDevice.
CONCLUSIONS: Pruning of the peripheral pulmonary vasculature is associated with asthma severity, control and exacerbations, as well as with lung function and eosinophilia. PMID: 29672122 [PubMed - as supplied by publisher]
Conclusion: The nonspecific chronic symptoms were high among auto-rickshaw drivers as compared to the general population noted from a multicentric study done in India. We recommend that auto-rickshaw drivers should use personal protective equipment and would require regular screening and treatment for respiratory impairment.
Health insurer Highmark inked an outcomes-based contract with AstraZeneca (NYSE:AZN) for Symbicort, the pharmaceutical company’s drug designed to treat asthma and chronic obstructive pulmonary disease. Highmark said its contract with AstraZeneca is one of the first outcomes-based deals involving a respiratory drug and will apply to commercial members of its national and core markets in Pennsylvania, West Virginia and Delaware. Get the full story at our sister site, Drug Delivery Business News. The post AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug appeared first on MassDevice.
The Clinical Respiratory Journal, EarlyView.
Electronic nose (eNose) and nuclear magnetic resonance (NMR)-based metabolomics seem to be able to identify metabolic and inflammatory profiles in patients with chronic obstructive diseases. The hypothesis arises from three recent studies using two different methods in patients with asthma and chronic obstructive pulmonary diseases (COPD), opening promising diagnostic perspectives. The possibility that the use of eNose and NMR-based metabolomics might provide clinical/inflammatory characteristics is intriguing.
Conclusions Existing respiratory disease, but not heart disease, was associated with increased air quality awareness. These findings reveal important opportunities to raise awareness of air quality alerts and behavior changes aimed at reducing air pollution exposure among adults at risk of exacerbating respiratory and heart diseases.
Conclusions The FOT is suitable and convenient for assessing therapeutic results in patients with tracheobronchial CAO. The alteration of R20 is useful for estimating the airway dilation of CAO after interventional bronchoscopy.
Conclusions: This is the first report that P-TEFb is involved in IL-17F-induced IL-8 expression and that steroids diminish it via the inhibition of CDK9 phosphorylation. IL-17F and P-TEFb might be novel therapeutic targets for airway inflammatory diseases.Int Arch Allergy Immunol
Chronic obstructive pulmonary disease (COPD) is characterised by persistent neutrophilic inflammation of the airways, which is associated with enhanced neutrophil extracellular trap (NET) formation of airway neutrophils [1–3]. NETs are web-like extracellular structures consisting of neutrophil DNA components and degradative enzymes (e.g. neutrophil elastase and myeloperoxidase) which are released from azurophilic granules by activated neutrophils . Initially found to immunoregulate host defence responses during bacterial infections, emerging data indicate that exaggerated NET formation and/or delayed NET clearance...
(New York Institute of Technology) Beta blockers have become a prescription drug staple for recovering heart attack patients. However, these blood pressure-reducing medications cannot be tolerated by many patients who are at higher risk for developing cardiovascular disease, including those with chronic obstructive pulmonary disease (COPD) and asthma, the elderly, and diabetics. As seen in the March 26 issue of Thyroid, researchers at New York Institute of Technology College of Osteopathic Medicine (NYITCOM) now pose a new treatment for patients with beta blocker intolerance: thyroid hormone therapy.